{"id":"foralumab-nasal","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nasopharyngitis"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1743020","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by targeting the CD3 receptor on T cells, leading to a reduction in inflammation and an increase in regulatory T cells. This results in a decrease in the immune system's response to autoimmune diseases.","oneSentence":"Foralumab Nasal is an anti-CD3 monoclonal antibody that modulates the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:33.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT06489548","phase":"PHASE2","title":"Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-09-16","conditions":"Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":16},{"nctId":"NCT06292923","phase":"PHASE2","title":"A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients","status":"RECRUITING","sponsor":"Tiziana Life Sciences LTD","startDate":"2023-11-15","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":54},{"nctId":"NCT06868628","phase":"PHASE2","title":"A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)","status":"RECRUITING","sponsor":"Tiziana Life Sciences LTD","startDate":"2025-05-19","conditions":"Multiple System Atrophy","enrollment":5},{"nctId":"NCT06890923","phase":"PHASE2","title":"Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Tiziana Life Sciences LTD","startDate":"2025-03-04","conditions":"Non-Active Secondary Progressive Multiple Sclerosis","enrollment":55},{"nctId":"NCT06802328","phase":"","title":"Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients","status":"AVAILABLE","sponsor":"Tiziana Life Sciences LTD","startDate":"","conditions":"Non-Active Secondary Progressive Multiple Sclerosis","enrollment":""},{"nctId":"NCT06879067","phase":"PHASE1","title":"Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers","status":"COMPLETED","sponsor":"Tiziana Life Sciences LTD","startDate":"2018-11-12","conditions":"Safety, Tolerability","enrollment":27},{"nctId":"NCT04983446","phase":"PHASE2","title":"In-patient COVID-19 Study of Intranasal Foralumab","status":"WITHDRAWN","sponsor":"Tiziana Life Sciences LTD","startDate":"2022-04-30","conditions":"Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection","enrollment":""},{"nctId":"NCT05029609","phase":"PHASE1","title":"Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS","status":"WITHDRAWN","sponsor":"Tiziana Life Sciences LTD","startDate":"2021-10","conditions":"Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Foralumab Nasal","genericName":"Foralumab Nasal","companyName":"Tiziana Life Sciences LTD","companyId":"tiziana-life-sciences-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Foralumab Nasal is an anti-CD3 monoclonal antibody that modulates the immune system. Used for Moderate to severe ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}